
APYX Stock Forecast & Price Target
APYX Analyst Ratings
Bulls say
Apyx Medical Corp reported a notable 31.4% year-over-year increase in total revenue for the third quarter of 2023, reaching $12.0 million, with the Advanced Energy segment driving a substantial 38.9% increase to $9.8 million. The company also experienced an improvement in gross margins, which rose 345 basis points year-over-year to 66.6%, indicating enhanced profitability amidst rising demand for its innovative products. Furthermore, Apyx has raised its OEM revenue guidance to $8.5 million and anticipates stronger growth in the second half of 2024 compared to the first half, suggesting a positive trajectory for the company's financial performance.
Bears say
Apyx Medical Corp's financial outlook has deteriorated due to a series of downward revisions in key metrics, including a reduction in 2023 revenue guidance to approximately $53 million, which is below consensus estimates. The company's gross margin forecast was also lowered to 66%, down from a previous range of 66.5% to 67.5%, reflecting a shortfall against market expectations and operational challenges. Furthermore, Apyx reported a non-GAAP loss per share of ($0.13), which was a significant miss of 44.4% compared to consensus, highlighting ongoing issues with sales execution and the impact of external economic factors on performance.
This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
APYX Analyst Forecast & Price Prediction
Start investing in APYX
Order type
Buy in
Order amount
Est. shares
0 shares